13F Holdings
中文EN

PALI PALISADE BIO, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357459 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-289.2%
TTM EPS YoY144.4%
Revenue 3-yr CAGR-98.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-9,625,400,000.0%
Net margin-8,739,200,000.0%
FCF margin—
EBITDA margin-9,625,400,000.0%

Returns

ROE-75.6%
ROA-69.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets5.1%
Debt / equity0.00x
Current ratio20.16x
Interest coverage-16,042.33x

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$250,000$0—
R&D expense$10.19M$16.00M$6.89M$6.55M$2.43M
SG&A expense$7.86M$5.80M$6.20M$8.76M$9.31M
Operating income-$18.06M-$14.86M-$13.07M-$15.72M-$41.85M
Interest expense$10,000$12,000$15,000$13,000$2.40M
Income tax$0$0$0$0$0
Net income-$16.78M-$14.44M-$12.30M-$14.26M-$26.62M
EBITDA-$18.05M-$14.86M-$13.07M-$15.72M-$41.85M
EPS (basic)-0.30-10.19-27.01-16.53-142.95
EPS (diluted)-0.30-10.19-27.01-16.53-169.74
Weighted avg. shares (diluted)55.67M1.42M456,014880,311186,958
Balance sheet
Cash & equivalents$133.38M$9.82M$12.43M$12.38M$10.49M
Receivables$0$0—$0$0
Current assets$134.22M$10.49M$13.33M$14.73M$11.51M
PP&E, net$0$3,000$10,000$10,000$3,000
Total assets$134.34M$10.88M$14.05M$15.76M$12.51M
Current liabilities$4.64M$3.24M$2.59M$3.01M$2.50M
Short-term debt————$87,000
Long-term debt————$0
Total debt————$87,000
Total liabilities$4.96M$3.39M$2.74M$3.28M$5.15M
Shareholders' equity$129.38M$7.49M$11.31M$12.48M$7.37M
Net debt————-$10.41M
Shares outstanding159.44M2.77M618,0562.94M284,780
Cash flow statement
Operating cash flow-$10.85M-$12.19M-$11.13M-$13.36M-$14.77M
Capital expenditure—$0$4,000$10,000$0
Free cash flow—-$12.19M-$11.14M-$13.37M-$14.77M
Investing cash flow—$0-$4,000-$10,000-$54,000
Financing cash flow$134.44M$9.58M$11.19M$15.26M$24.61M
Depreciation & amortization$3,000$3,000$4,000$3,000$2,000
Stock-based compensation$3.96M$652,000$624,000$1.03M$1.89M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.